Resistance mechanisms to SYK inhibition in acute myeloid leukemia

Spleen tyrosine kinase (SYK) is a non-mutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechanisms of resistance to single agent treatment in vivo. We con...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Cremer, Anjali, Ellegast, Jana M., Alexe, Gabriela, Frank, Elizabeth S., Ross, Linda, Chu, S. Haihua, Pikman, Yana, Robichaud, Amanda, Goodale, Amy, Häupl, Björn, Mohr, Sebastian, Rao, Arati V., Walker, Alison R., Blachly, James S., Piccioni, Federica, Armstrong, Scott A., Byrd, John C., Oellerich, Thomas, Stegmaier, Kimberly
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058374/
https://ncbi.nlm.nih.gov/pubmed/31771968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0209
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados